Allogeneic Hematopoietic Cell Transplant Clinical Trials

3 recruiting

Allogeneic Hematopoietic Cell Transplant Trials at a Glance

9 actively recruiting trials for allogeneic hematopoietic cell transplant are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Cleveland, Boston, and Atlanta. Lead sponsors running allogeneic hematopoietic cell transplant studies include Pierre Fabre Medicament, Dana-Farber Cancer Institute, and Children's Hospital Medical Center, Cincinnati.

Browse allogeneic hematopoietic cell transplant trials by phase

Treatments under study

About Allogeneic Hematopoietic Cell Transplant Clinical Trials

Looking for clinical trials for Allogeneic Hematopoietic Cell Transplant? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Allogeneic Hematopoietic Cell Transplant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Allogeneic Hematopoietic Cell Transplant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Acute LeukemiaMyelodysplastic SyndromesMyeloproliferative Disorders+3 more
Stanford University77 enrolled1 locationNCT05088356
Recruiting
Phase 3

MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib

Acute Myeloid Leukemia (AML)Maintenance TherapyAllogeneic Hematopoietic Cell Transplantation (HCT)+3 more
The First Affiliated Hospital of Soochow University594 enrolled2 locationsNCT07463651
Recruiting
Phase 3

Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation

Allogeneic Hematopoietic Cell Transplant
Shanghai Jiao Tong University School of Medicine316 enrolled1 locationNCT06705062
Recruiting
Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting
Early Phase 1

Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation
Case Comprehensive Cancer Center20 enrolled1 locationNCT04332341
Recruiting
Phase 2

Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML

AML (Acute Myeloid Leukemia)Allogeneic Hematopoietic Cell Transplantation (HCT)
Institute of Hematology & Blood Diseases Hospital, China134 enrolled5 locationsNCT07304232
Recruiting
Not Applicable

Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation

Oral MucositisMyeloablative Allogeneic Hematopoietic Cell TransplantationIntraoral Photobiomodulation Therapy+1 more
Dana-Farber Cancer Institute20 enrolled1 locationNCT05335434
Recruiting
Phase 2

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation
Children's Hospital Medical Center, Cincinnati60 enrolled1 locationNCT05501756